GlassScriptPhysician profile
Aruna Gullapalli
NPI 1154303261
$9,942.71
in general payments reported to CMS, 2019-2025
30 companies · $946 in 2025
The $946 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,185 · 2020: $1,316 · 2021: $1,341 · 2022: $1,157 · 2023: $1,257 · 2024: $741 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,944.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,533.77 | 2021-2025 | |
| Allergan, INC. | $1,430.24 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $1,232.57 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $856.04 | 2019-2022 | |
| Alkermes, INC. | $780.85 | 2019-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $562.26 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $440.87 | 2019-2023 | Austedo Xr, Austedo |
| Corium, LLC | $411.89 | 2022-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $396.15 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $361.04 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $338.86 | 2019-2023 | Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $274.25 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $180.87 | 2023-2025 | Auvelity |
| Shire North American Group INC | $171.83 | 2019 | |
| Vanda Pharmaceuticals INC. | $170.75 | 2019-2025 | Fanapt |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $163.56 | 2021-2024 | Qelbree, Qelbree |
| Indivior INC. | $159.15 | 2022-2024 | Perseris |
| Ironshore Pharmaceuticals INC. | $87.75 | 2019-2022 | |
| Eisai INC. | $72.38 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $61.57 | 2023-2024 | Quviviq |
| Noven Therapeutics, LLC | $58.72 | 2024-2025 | Xelstrym, Secuado |
| E.R. Squibb & Sons, L.L.C. | $38.97 | 2025 | Cobenfy |
| Adlon Therapeutics L.P. | $36.80 | 2020 | |
| Merck Sharp & Dohme LLC | $35.92 | 2020 | |
| Neos Therapeutics, LP | $20.67 | 2019 | |
| Tris Pharma INC | $19.55 | 2022 | |
| Collegium Pharmaceutical, INC. | $16.24 | 2025 | Jornay Pm |
| Neuronetics, INC. | $15.30 | 2020 | |
| Bausch Health US, LLC | $13.89 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aruna Gullapalli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.